KR20240122521A - 만성 신장 질환 치료용 알도스테론 신타아제 억제제 - Google Patents

만성 신장 질환 치료용 알도스테론 신타아제 억제제 Download PDF

Info

Publication number
KR20240122521A
KR20240122521A KR1020247023466A KR20247023466A KR20240122521A KR 20240122521 A KR20240122521 A KR 20240122521A KR 1020247023466 A KR1020247023466 A KR 1020247023466A KR 20247023466 A KR20247023466 A KR 20247023466A KR 20240122521 A KR20240122521 A KR 20240122521A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
formula
treatment
ckd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023466A
Other languages
English (en)
Korean (ko)
Inventor
리사 브이. 크로닌
지빌레 예니 하우스케
하르트무트 뤼텐
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20240122521A publication Critical patent/KR20240122521A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247023466A 2021-12-14 2022-12-13 만성 신장 질환 치료용 알도스테론 신타아제 억제제 Pending KR20240122521A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289177P 2021-12-14 2021-12-14
US63/289,177 2021-12-14
PCT/US2022/052631 WO2023114170A1 (en) 2021-12-14 2022-12-13 Aldosterone synthase inhibitors for treating chronic kidney disease

Publications (1)

Publication Number Publication Date
KR20240122521A true KR20240122521A (ko) 2024-08-12

Family

ID=85151059

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023466A Pending KR20240122521A (ko) 2021-12-14 2022-12-13 만성 신장 질환 치료용 알도스테론 신타아제 억제제

Country Status (12)

Country Link
US (2) US12263157B2 (https=)
EP (1) EP4447961A1 (https=)
JP (1) JP2025500826A (https=)
KR (1) KR20240122521A (https=)
CN (1) CN118401241A (https=)
AR (1) AR127948A1 (https=)
AU (1) AU2022415313A1 (https=)
CA (1) CA3236890A1 (https=)
CL (1) CL2024001470A1 (https=)
MX (1) MX2024007335A (https=)
TW (1) TW202339719A (https=)
WO (1) WO2023114170A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019546A1 (en) * 2023-07-17 2025-01-23 Mineralys Therapeutics, Inc. Methods of treating chronic kidney disease (ckd) or ckd and hypertension with lorundrostat, or a combination of lorundrostat and a sglt2 inhibitor
TW202525278A (zh) * 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法
US20250255851A1 (en) * 2024-02-14 2025-08-14 Boehringer Ingelheim International Gmbh Solid forms of an aldosterone synthase inhibitor
WO2025190858A1 (en) * 2024-03-12 2025-09-18 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitor for treating heart failure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008959A1 (fr) 1992-10-20 1994-04-28 Taisho Pharmaceutical Co., Ltd. Derive de prostaglandine
AU714033B2 (en) 1996-07-19 1999-12-16 Nissan Chemical Industries Ltd. Method for producing purified epoxy compound
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
ZA200500918B (en) 2002-10-15 2006-12-27 Otsuka Pharma Co Ltd 1-substituted 4-nitroimidazole compound and process for producing the same
CA2494710C (en) 2002-10-15 2011-05-03 Otsuka Pharmaceutical Co., Ltd. 1-substituted-4-nitroimidazole compound and method for preparing the same
EP1996588A4 (en) 2006-03-03 2011-10-05 Torrent Pharmaceuticals Ltd NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS
EP2001866A2 (en) 2006-03-29 2008-12-17 Novartis AG Organic compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
JP2007297305A (ja) 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
CA2660701A1 (en) 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010016987A1 (en) 2008-08-05 2010-02-11 Dow Global Technologies Inc. Production of solid epoxy resin
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
TW201026688A (en) 2008-10-07 2010-07-16 Schering Corp Benzodioxan analogues as alpha2C adrenergic receptor modulators
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
CA2761009A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
BR112012002214B1 (pt) 2009-07-31 2022-01-25 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina e nitroimidazooxazol, seus usos e composição farmacêutica
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
HRP20192323T1 (hr) 2011-09-15 2020-03-20 F. Hoffmann - La Roche Ag Novi derivati dihidrokinolin-2-ona
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
AR088989A1 (es) 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
HRP20171996T1 (hr) 2012-04-17 2018-02-09 F. Hoffmann - La Roche Ag Novi derivati fenil-tetrahidroizokinolina
KR102096927B1 (ko) 2012-09-04 2020-04-06 삼성전자주식회사 제어 채널 엘리먼트들에 대한 어그리게이션 레벨들 개수 조정 장치 및 방법
CA2886117C (en) 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
US8912341B2 (en) 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014168861A2 (en) 2013-04-08 2014-10-16 Cowans Kenneth W Air supply concepts to improve efficiency of vcrc engines
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
JP6067181B2 (ja) 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
JP6471153B2 (ja) 2013-10-17 2019-02-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体
KR20160100408A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
HUE039981T2 (hu) 2014-07-24 2019-02-28 Boehringer Ingelheim Int Aldoszteron szintáz inhibitorok
WO2016061161A1 (en) 2014-10-15 2016-04-21 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
WO2016119706A1 (zh) 2015-01-29 2016-08-04 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
KR20190084096A (ko) 2016-11-10 2019-07-15 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
CN109053637B (zh) 2018-08-14 2021-03-16 杭州泽旺生物科技有限公司 尺蠖类性信息素及其中间体的合成方法

Also Published As

Publication number Publication date
EP4447961A1 (en) 2024-10-23
US12263157B2 (en) 2025-04-01
AU2022415313A1 (en) 2024-05-02
US20250049763A1 (en) 2025-02-13
US20230181538A1 (en) 2023-06-15
JP2025500826A (ja) 2025-01-15
MX2024007335A (es) 2024-06-26
CL2024001470A1 (es) 2024-09-13
TW202339719A (zh) 2023-10-16
CA3236890A1 (en) 2023-06-22
CN118401241A (zh) 2024-07-26
AR127948A1 (es) 2024-03-13
WO2023114170A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
KR20240122521A (ko) 만성 신장 질환 치료용 알도스테론 신타아제 억제제
JP3546058B2 (ja) うっ血性心不全の治療へのカルバゾール化合物の利用
US6548518B2 (en) Methods of treating gastro-esophogeal reflux disease using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
EP2411006B1 (en) Compositions and methods for treatment of renal disease
WO1995014384A1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
JP2012025756A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
EP1156852A2 (en) Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h 2? receptor antagonists
AU2025271047A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CN108349900A (zh) 雄激素受体拮抗剂
MX2011000511A (es) Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis.
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
AU2013216864A1 (en) Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
US20230277523A1 (en) Methods for inhibiting phosphate transport
EP3025711B1 (en) Medicine for preventing or treating hypertension
JP6726138B2 (ja) （３ｓ，３ｓ’）４，４’−ジスルファンジイルビス（３−アミノブタン １−スルホン酸）および第２の抗高血圧剤の組合せ
SG185474A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
EP3332779A1 (en) Ameliorating agent for detrusor hyperactivity with impaired contractility
TW201737909A (zh) 用以腎臟病之治療的醫藥
JP2017528517A (ja) 多汗症を治療するための方法
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
WO2025171012A1 (en) Methods of treatment using an ezh2 modulator
CN103040841B (zh) 一种含厄贝沙坦和氢氯噻嗪的药物组合物
AU2010229771B2 (en) Compositions and methods for treatment of renal disease
IL303118A (en) Dosing of fedratinib
Swapna et al. A Randomised Clinical Active Control Study to Assess the Safety and Efficacy of Nifedipine Besilate Comparated with Telmestran in Patients Suffering with Essential Hypertension

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000